Recruiting trial = ; Ongoing trial = ; Terminated trial = ; Funded by an IRDiRC member = ; Study involving ERN members in at least two Member States =

National clinical trial(s)

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) - AT

Institution: Information not provided - AT

More details

NETHERLANDS

Utrecht
UTRECHT

PPI Shine Again: Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial

UMC Utrecht - Universitair Medisch Centrum Utrecht

Van Creveldkliniek

More details

Multinational clinical trial(s)

SWITZERLAND

Suisse Romande
ADDRESS: NOT PROVIDED - CH

An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low- and int-1-risk myelodysplastic syndrome

Institution: Information not provided - CH

More details

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to compare the efficacy and safety of lenalidomide (Revlimid) versus placebo in subjects with transfusion-dependent anemia due to IPSS low or intermediate-1 risk myelodysplastic syndromes without deletion 5q[31] and unresponsive or refractory to erythropoiesisstimulating agents

Institution: Information not provided - US

More details